TY - JOUR T1 - Systems medicine advances in interstitial lung disease JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0021-2017 VL - 26 IS - 145 SP - 170021 AU - Flavia R. Greiffo AU - Oliver Eickelberg AU - Isis E. Fernandez Y1 - 2017/09/30 UR - http://err.ersjournals.com/content/26/145/170021.abstract N2 - Fibrotic lung diseases involve subject–environment interactions, together with dysregulated homeostatic processes, impaired DNA repair and distorted immune functions. Systems medicine-based approaches are used to analyse diseases in a holistic manner, by integrating systems biology platforms along with clinical parameters, for the purpose of understanding disease origin, progression, exacerbation and remission.Interstitial lung diseases (ILDs) refer to a heterogeneous group of complex fibrotic diseases. The increase of systems medicine-based approaches in the understanding of ILDs provides exceptional advantages by improving diagnostics, unravelling phenotypical differences, and stratifying patient populations by predictable outcomes and personalised treatments. This review discusses the state-of-the-art contributions of systems medicine-based approaches in ILDs over the past 5 years.Systems medicine provides critical advances in understanding and molecular fingerprinting interstitial lung diseases http://ow.ly/phXg30dWVvv ER -